Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended October 31, 2001
Business Overview: The Company manufactures laboratory and technical products. Operations are divided into Laboratory Products and Technical Products segments.
Key Financial Metrics
| Metric ($ in thousands) | 3 Months Ended Oct 31, 2001 | 6 Months Ended Oct 31, 2001 |
|---|---|---|
| Net Sales | $22,525 | $42,265 |
| Gross Profit | $3,934 | $7,141 |
| Gross Margin | 17.5% | 16.9% |
| Operating Earnings | $1,076 | $1,531 |
| Net Earnings | $638 | $931 |
| Diluted EPS | $0.26 | $0.38 |
| Cash from Operations | N/A | ($11) |
| Working Capital | $15,395 | $15,395 |
| Short-term Borrowings | $1,714 | $1,714 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.2% for the quarter and 3.6% for the six-month period compared to the prior year.
- Segment Divergence: Laboratory Products sales rose significantly (19.5% for the quarter, 22.0% for six months), while Technical Products sales declined sharply (59.5% for the quarter, 61.4% for six months) due to reduced high-tech capital spending.
- Margin Compression: Gross profit margins decreased from 20.2% to 17.5% (quarter) and 19.6% to 16.9% (six months). This was driven by the shift in sales mix toward lower-margin laboratory products and unfavorable mix within that segment.
- Expense Management: Operating expenses decreased as a percentage of sales (12.7% vs. 14.1% for the quarter) due to lower marketing and general/administrative costs.
- Profitability: Net earnings declined 18.4% for the quarter and 6.5% for the six-month period compared to the prior year.
- Liquidity: Cash and cash equivalents decreased from $488,000 to $409,000. The Company utilized $1,714,000 of its $6.0 million revolving credit facility.
Outlook, Risks, and Management Commentary
- Market Conditions: Management cites continuing improvement in the industrial research and education markets for laboratory products, contrasted with a slowdown in high-tech capital spending affecting technical products.
- Liquidity Outlook: The Company believes funds from operations and short-term borrowings are sufficient to support ongoing business and capital expenditures through the current fiscal year.
- Capital Expenditures: Capital spending was $1,029,000 for the six months ended October 31, 2001, primarily for production equipment, down from $1,513,000 in the prior year.
- Risks: Forward-looking statements are subject to economic, competitive, governmental, and technological factors. The Company notes it cannot always predict factors causing actual results to differ from expectations.
Investor Verification Checklist
- Verify the sustainability of the 19.5% growth in Laboratory Products sales versus the 59.5% decline in Technical Products.
- Monitor the impact of the shifting product mix on future gross margins, which have compressed to 16.9%.
- Review the utilization of the $6.0 million revolving credit facility ($1.7M currently outstanding) and its effect on interest expense.
- Assess the cash flow trend, noting the shift from positive operating cash flow ($746k prior year) to negative operating cash flow ($11k current year) driven by increases in receivables and inventories.
- Confirm the accuracy of the $3.5M increase in receivables and $672k increase in inventories over the six-month period.